Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge. Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to cytotoxic drugs is a common theme in cancer. Targeting BCL-2 with the BH3-mimetic venetoclax is active in AML when combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moujalled, Donia M., Pomilio, Giovanna, Ghiurau, Corina, Ivey, Adam, Salmon, Jessica, Rijal, Sewa, Macraild, Sarah, Zhang, Lan, Teh, Tse-Chieh, Tiong, Ing-Soo, Lan, Ping, Chanrion, Maia, Claperon, Audrey, Rocchetti, Francesca, Zichi, Adrien, Kraus-Berthier, Laurence, Wang, Youzhen, Halilovic, Ensar, Morris, Erick, Colland, Frédéric, Segal, David, Huang, David, Roberts, Andrew W., Maragno, Ana Leticia, Lessene, Guillaume, Geneste, Olivier, Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484700/
https://www.ncbi.nlm.nih.gov/pubmed/30214012
http://dx.doi.org/10.1038/s41375-018-0261-3

Ejemplares similares

Ejemplares similares